Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes Care securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the specified Class Period from December 4, 2024, to September 9, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Synopsys failed to disclose significant adverse facts about its business, particularly regarding its focus on artificial intelligence customers, which negatively impacted its Design IP business [5]. - Defendants allegedly made positive statements about Synopsys' business that were misleading and lacked a reasonable basis, leading to investor damages when the truth was revealed [5]. Group 2: Investor Information - Investors who purchased Synopsys securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years, including over $438 million secured in 2019 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Lantheus Holdings, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on November 10, 2025 [1]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Lantheus provided misleading statements regarding the competitive position of its product, Pylarify, while failing to disclose critical information about pricing and market dynamics [5]. - It is claimed that Lantheus's early 2025 price increase, despite previous price erosion, created opportunities for competitive pricing that jeopardized Pylarify's market position and revenue potential [5].

Core Points - Rosen Law Firm is reminding investors of Lantheus Holdings, Inc. about the November 10, 2025 deadline to join a securities class action lawsuit related to the company's stock performance during the Class Period from February 26, 2025, to August 5, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased Lantheus securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [3]. - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify, failing to disclose critical information regarding its competitive position and pricing strategy [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and has recovered hundreds of millions for investors [4]. Group 3: Case Background - The lawsuit claims that Lantheus made overwhelmingly positive statements while concealing material adverse facts about Pylarify's market position, which led to investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of CarMax, Inc. investors for securities purchased between June 20, 2025, and November 5, 2025, due to alleged misleading statements regarding the company's growth prospects [2][6]. Group 1: Lawsuit Details - The class action lawsuit claims that CarMax's defendants made materially false and misleading statements about the company's growth, overstating its prospects based on temporary benefits from customer behavior influenced by tariff speculation [6]. - Investors who purchased CarMax securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. Group 2: Next Steps for Investors - Investors interested in joining the CarMax class action can do so by visiting the provided link or contacting the law firm directly, with a deadline to serve as lead plaintiff by January 2, 2026 [4][7]. - It is noted that no class has been certified yet, and investors are encouraged to select qualified counsel with a proven track record in securities class actions [5][8]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong reputation in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has consistently ranked highly in terms of the number of securities class action settlements and has recovered hundreds of millions of dollars for investors over the years [5].

Core Viewpoint - Rosen Law Firm is reminding purchasers of WPP plc American Depositary Shares (ADS) of the upcoming lead plaintiff deadline for a class action lawsuit, which is set for December 8, 2025 [1]. Group 1: Class Action Details - Investors who purchased WPP ADSs between February 27, 2025, and July 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit claims that WPP provided misleading statements about its media arm's capabilities, which led to significant market share loss and investor damages when the truth was revealed [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured substantial settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action settlements [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Actions and Investigations - Shareholders who purchased Telix securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission regarding disclosures related to its prostate cancer therapeutic candidates, leading to a 10.44% drop in the price of Telix's American Depositary Shares on July 23, 2025 [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The deadline to move the Court to serve as lead plaintiff is December 15, 2025, with the lead plaintiff acting on behalf of other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific claims include that Baxter was aware of multiple device malfunctions and that its remedial measures were inadequate, resulting in a heightened risk of product recalls and sales pauses [5] - The lawsuit asserts that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, causing investor damages when the truth was revealed [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 15, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Baxter - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to malfunctions and posed serious risks to patients [5]. - Specific issues cited include underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate remedial measures taken by Baxter in response to reported malfunctions and injuries [5]. - The lawsuit claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the true details became public [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of aTyr Pharma, Inc. to secure legal counsel before the December 8, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - The class period for the aTyr Pharma securities class action is from January 16, 2025, to September 12, 2025 [1]. - Investors who purchased aTyr Pharma common stock during this period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 8, 2025 [3]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Allegations - The complaint alleges that aTyr Pharma's defendants made misleading statements regarding the efficacy of the drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [5]. - The lawsuit claims that when the true information became public, investors suffered damages as a result of these misleading statements [5].